ClinicalTrials.gg
CompletedNCT01181310Updated Nov 6, 2015

Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)

A Phase 1 interventional study of A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine and B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg in Dementia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing donepezil in Dementia — none open to participants now, none under way, none of them phase 3. Donepezil · Dementia.

Enrollment
20th of 24
31 · median 151
Started
2007
with 2 others
Phase 1
Only one
of the 26
Registered
15th of 26
by date

Among the 26 studies testing donepezil in Dementia, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2007, is the only one in phase 1, and was the 15th registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

Browse Dementia studies →

Open to participants now

None of the 26 studies testing donepezil in Dementia is open now. The open studies under Dementia, anywhere →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing donepezil in Dementia as a file.
02

Study summary

The drug, scopolamine, can result in short-term impairments of cognitive function, attention, and memory that resemble those seen in aging and Alzheimer's disease. This study tested the capability of both individual and combined doses of MK-3134 and the current standard treatment: donepezil (Aricept), to reverse such impairments, following a single dose of scopolamine. Participants were evaluated after each of 5 different treatment periods (in a cross-over, double-dummy design): A: placebo to match both donepezil (oral [PO]) and MK-3134 (PO) followed by placebo scopolamine (subcutaneous [SQ]); B: placebo to match both donepezil (PO) and MK-3134 (PO), followed by scopolamine SQ; C: MK-3134 (PO) followed by scopolamine SQ; D: donepezil (PO) followed by scopolamine SQ; E: MK-3134 (PO) and donepezil (PO) followed by scopolamine SQ. The doses of MK3134, donepezil, and scopolamine were the same over all treatment arms in which the specified drug was administered. There were 8 total visits for each treatment period, including 5 Treatment Visits requiring 14-day intervals between visits for study-drug washout. Participants were assessed for cognitive function before and after each treatment period during the Treatment Visits.

03

Conditions studied

  • Dementia

Keywords

  • dementia, cognitive impairment, neurodegeneration, Alzheimer's, acetylcholine, AchE
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Participants were eligible for inclusion in the study who were:

  • Male between 18 and 40 years of age.
  • Non-smokers, in good health (as defined in protocol), and were willing to follow study-related procedures.

Participants were not eligible for inclusion in the study if they:

  • Had a history of illness that, in the opinion of the study investigator or as specified in protocol, might confound the results of the study or posed an potential, additional risk to the participant if they were to participate in the study.
  • Were taking any medication (prescription, nonprescription, vitamin supplements or herbal, illicit or legitimate) except for acetaminophen.
  • Had a history of any significant head injury/trauma.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    A, B, D, E, C

    Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    B, C, E, A, D

    Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    C, D, A, B, E

    Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    D, E, B, C, A

    Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    E, A, C, D, B

    Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    A, C, B, E, D

    Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    B, D, C, A, E

    Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    C, E, D, B, A

    Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    D, A, E, C, B

    Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

  • Experimental
    E, B, A, D, C

    Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.

    Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine · Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg · Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg · Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg · Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

Interventions

  • DrugA: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine

    Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.

  • DrugB: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg

    Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.

  • DrugC: MK-3134 25 mg + Scopolamine 0.5 mg

    A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.

  • DrugD: Donepezil 10 mg + Scopolamine 0.5 mg

    Drug page: Donepezil

    A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

    Also known as: Aricept (donepezil)

  • DrugE: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

    Drug page: Donepezil

    A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.

    Also known as: Aricept (donepezil)

06

What researchers measure

Primary outcomes

  1. CogState Early Phase Battery, Groton Maze Learning Test (GMLT) as measured by the number of errors on the GMLT over time (area under the GMLT-time curve) over hours 1-12.

    Participants learned a hidden pathway through a maze (10 x 10 grid of tiles on a computer touch screen) using step-by-step guess, with trial and error feedback after each step. Once the pathway was learned, participants repeated the same pathway four more times. The number of pathway errors was used to indicate the level of cognitive function.

    Time frame: 1, 2, 3, 4, 6, 8, and 12 hours relative to administration of SQ scopolamine or SQ placebo

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Cho W, Maruff P, Connell J, Gargano C, Calder N, Doran S, Fox-Bosetti S, Hassan A, Renger J, Herman G, Lines C, Verma A. Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011 Dec;218(3):513-24. doi: 10.1007/s00213-011-2344-y. Epub 2011 Jun 7. PubMed 21644059 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2010
First posted
Aug 13, 2010
Start
Jun 2007
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Last update
Nov 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01181310
Responsible party
Sponsor
First posted
Aug 13, 2010
Start date
Jun 2007
Primary completion
Oct 2007
Completion
Oct 2007
Last update
Nov 6, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion